F
Farid Ahmad Siddiqui
Researcher at Åbo Akademi University
Publications - 16
Citations - 338
Farid Ahmad Siddiqui is an academic researcher from Åbo Akademi University. The author has contributed to research in topics: Cancer & PKM2. The author has an hindex of 8, co-authored 16 publications receiving 215 citations. Previous affiliations of Farid Ahmad Siddiqui include University of Turku & Jamia Millia Islamia.
Papers
More filters
Journal ArticleDOI
Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition.
Farid Ahmad Siddiqui,Gopinath Prakasam,Shilpi Chattopadhyay,Asad Ur Rehman,Rayees Ahmad Padder,Mohammad Afaque Ansari,Rasha Irshad,Kailash Chandra Mangalhara,Rameshwar N. K. Bamezai,Mohammad Husain,Syed Mansoor Ali,Mohammad Askandar Iqbal +11 more
TL;DR: It is shown that curcumin inhibits glucose uptake and lactate production (Warburg effect) in a variety of cancer cell lines by down-regulating PKM2 expression, via inhibition of mTOR-HIF1α axis, and PKM 2 over-expression abrogated the effects ofCurcumin, demonstrating that inhibition of Warburg effect by curcuming is PKM1-mediated.
Journal ArticleDOI
Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2
Mohd Askandar Iqbal,Farid Ahmad Siddiqui,Vibhor Gupta,Shilpi Chattopadhyay,Prakasam Gopinath,Bhupender Kumar,Siddharth Manvati,Noor Chaman,Rameshwar N. K. Bamezai +8 more
TL;DR: The study identifies new PKM2-mediated effects of insulin on cancer metabolism, thus, advancing the understanding of insulin’s role in cancer.
Journal ArticleDOI
Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Mohammad Askandar Iqbal,Shilpi Chattopadhyay,Farid Ahmad Siddiqui,Farid Ahmad Siddiqui,Asad Ur Rehman,Asad Ur Rehman,Shumaila Siddiqui,Gopinath Prakasam,Gopinath Prakasam,Asifa Khan,Sarwat Sultana,Rameshwar N. K. Bamezai +11 more
TL;DR: The results highlight the importance of EGFR‐MYC‐TXNIP axis in regulating TNBC metabolism, demonstrate the anti‐TNBC activity of silibinin, and argue in favor of targeting metabolic vulnerabilities of TNBC, at least in combination with mainstay chemotherapeutic drugs, to effectively treat TNBC patients.
Journal ArticleDOI
PDE6D Inhibitors with a New Design Principle Selectively Block K-Ras Activity
Farid Ahmad Siddiqui,Catharina Alam,Petja Rosenqvist,Mikko Ora,Ahmed Sabt,Ganesh babu Manoharan,Lakshman Bindu,Sunday Ojochegbe Okutachi,Marie Catillon,Troy Taylor,Omaima M. Abdelhafez,Harri Lönnberg,Andrew G. Stephen,Anastassios C. Papageorgiou,Pasi Virta,Daniel Abankwa,Daniel Abankwa +16 more
TL;DR: A modular and simple inhibitor redesign is engineered into prenyl-binding pocket inhibitors of PDE6D to increase resilience against ejection and could significantly advance the development of pharmacologically more potent compounds against PDE 6D and related targets, such as UNC119 in the future.
Journal ArticleDOI
Missense Mutations in Pyruvate Kinase M2 Promote Cancer Metabolism, Oxidative Endurance, Anchorage Independence, and Tumor Growth in a Dominant Negative Manner
Mohd Askandar Iqbal,Farid Ahmad Siddiqui,Noor Chaman,Vibhor Gupta,Bhupender Kumar,Prakasam Gopinath,Rameshwar N. K. Bamezai +6 more
TL;DR: This study provides the first evidence linking natural mutations in PKM2 with cancer, and demonstrates for the first time the possible predisposition of Bloom syndrome patients with impaired PKM1 activity to cancer and the importance of studying genetic variations inPKM2 in the future to understand their relevance in cancer in general.